Anglés-Cano E - Search Results

1

Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.

de Souza JG, Morais KL, Anglés-Cano E, Boufleur P, de Mello ES, Maria DA, Origassa CS, de Campos Zampolli H, Câmara NO, Berra CM, Bosch RV, Chudzinski-Tavassi AM. de Souza JG, et al. Oncotarget. 2016 Sep 20;7(38):62255-62266. doi: 10.18632/oncotarget.11555. Oncotarget. 2016. PMID: 27566592 Free PMC article.

2

Fibrino(geno)lytic properties of purified hementerin, a metalloproteinase from the leech Haementeria depressa.

Chudzinski-Tavassi AM, Kelen EM, de Paula Rosa AP, Loyau S, Sampaio CA, Bon C, Anglés-Cano E. Chudzinski-Tavassi AM, et al. Thromb Haemost. 1998 Jul;80(1):155-60. Thromb Haemost. 1998. PMID: 9684802

3

Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation.

Martínez C, Rivera J, Loyau S, Corral J, González-Conejero R, Lozano ML, Vicente V, Anglés-Cano E. Martínez C, et al. Thromb Haemost. 2001 Apr;85(4):686-93. Thromb Haemost. 2001. PMID: 11341506

4

Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin--a study with individual plasmas presenting natural variations of Lp(a).

Soulat T, Loyau S, Baudouin V, Durlach V, Gillery P, Garnotel R, Loirat C, Anglés-Cano E. Soulat T, et al. Thromb Haemost. 1999 Jul;82(1):121-7. Thromb Haemost. 1999. PMID: 10456465

5

Inhibition of fibrinolysis by lipoprotein(a).

Anglés-Cano E, de la Peña Díaz A, Loyau S. Anglés-Cano E, et al. Ann N Y Acad Sci. 2001;936:261-75. doi: 10.1111/j.1749-6632.2001.tb03514.x. Ann N Y Acad Sci. 2001. PMID: 11460483 Review.

6

Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface.

Fleury V, Loyau S, Lijnen HR, Nieuwenhuizen W, Anglés-Cano E. Fleury V, et al. Eur J Biochem. 1993 Sep 1;216(2):549-56. doi: 10.1111/j.1432-1033.1993.tb18173.x. Eur J Biochem. 1993. PMID: 8375393 Free article.

7

Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism.

Angles-Cano E, Gris JC, Loyau S, Schved JF. Angles-Cano E, et al. J Lab Clin Med. 1993 May;121(5):646-53. J Lab Clin Med. 1993. PMID: 8478593

8

Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome.

Soulat T, Loyau S, Baudouin V, Maisonneuve L, Hurtaud-Roux MF, Schlegel N, Loirat C, Anglés-Cano E. Soulat T, et al. Arterioscler Thromb Vasc Biol. 2000 Feb;20(2):575-84. doi: 10.1161/01.atv.20.2.575. Arterioscler Thromb Vasc Biol. 2000. PMID: 10669658

9

Functional approach to investigate Lp(a) in ischaemic heart and cerebral diseases.

de la Peña-Díaz A, Cardoso-Saldaña G, Zamora-González J, Barinagarrementeria F, Izaguirre R, Loyau S, Anglés-Cano E. de la Peña-Díaz A, et al. Eur J Clin Invest. 2003 Feb;33(2):99-105. doi: 10.1046/j.1365-2362.2003.01114.x. Eur J Clin Invest. 2003. PMID: 12588282

10

Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?

Hervio L, Chapman MJ, Thillet J, Loyau S, Anglés-Cano E. Hervio L, et al. Blood. 1993 Jul 15;82(2):392-7. Blood. 1993. PMID: 8329699 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

148 results

Search Page

Filters